Over the past few years, the focus in interventional cardiology research has centered on reducing restenosis with the use of antiproliferative pharmacological agents.

The use of these drugs, hitherto, has failed, most probably because of low active drug levels at the target site.

This problem led to the development of local drug delivery using stents, since they can serve as a reservoir for local drug administration and are in immediate contract with the coronary artery wall, thus ensuring maximum delivery of the pharmacological agent.

Drug-eluting stents provide an entirely new spectrum of potential therapies for restenosis.

Drug Eluting Stents Handbook provides the reader with up-to-date information on which stents and pharmacological agents in use or about to be launched, the kinetics of the drugs involved, and what the future may hold.

Contents:

1. Historical Notes of Early Failures and Later Successes with Local Drug Delivery
2. The Clinical Problem of Restenosis
3. Histopathology of Restenosis Cellular Mechanism of Restenosis, with Conventional Dogma And Novel Therapies
4. Molecular Basis of Restenosis: Potential Target and Agents for Local Drug Delivery
5. Principles and Kinetics of Stent-Based Drug Elution
6. Importance of the Toxic/Therapeutic Window
7. Importance of the Polymer
8. The Importance of the Drug Platform: Coated, Uncoated, Sleeves, and New Concepts
9. Cypher Programme of Cordis/Johnson & Johnson
10. Rapamycin Structures and Mechanism of Action
11. Rapamycin: Preclinical Studies
12. Non-Randomized Registries for De Novo Lesion (FIM) and Instent Restenosis
13. Randomized Trial (RAVEL) and Further Clinical Developments (SIRIUS)
14. Quanam Programme with Taxol Derivative (PILOT Study and SCORE Trial)
15. Taxus Programme of Boston Scientific
16. Paclitaxel Structures and Mechanism of Action
17. Preclinical Studies for the Taxus Programme
18. Non-Randomized Registries for De Novo Lesion (TAXUS I) and Instent Restenosis (TAXUSIII)
19. Randomized Trial (TAXUS II And IV) and Further Clinical Developments
20. The Cook Inc Paclitaxel Programme
21. Preclinical Studies
22. Clinical Programme
23. Aspect Patency Elutes and Future Studies
24. VEGF
25. The Guidant Actinomycin-D/Pharmalink Programme
26. Actinomycin Structures and Mechanisms of Action
27. Actinomycin: Preclinical Studies
28. Randomized Trial (ACTION, Europe; and OPEN USA) and Further Clinical Developments
29. The Biodivisio Programme
30. Angiopeptin: Mode of Action, Preclinical and Clinical Studies (SWAN)
31. Batimastat: Mode of Action, Preclinical and Clinical Studies (BRILLIANT)(BATMAN)(ROBIN)(DISTINCT)
32. Matrix Compounds
33. Dexamethasone: Mode of Action, Preclinical and Clinical Studies (STRIDE)
34. 17-Beta-Estradiol
35. Medtronic Programme
36. Antisense Oligonucleotides Against C-Myc (AVI4126 Biopharma): Current Status and Future
37. Developments
38. Orbus Programme of Eluting Stents
39. Igaki Tamai Programme
40. Biodegradable Stent (Tranilast and Inhibitors of Tyrosine Kinase)
41. Terumo Programme
42. Terumo Statin Releasing Stent (Preclinical Results)
43. JOMED Programme
44. Potential Agents in Development
45. Halofuginone, a Collagen Inhibitor

click here to see books • videos • cd-roms of related interest

ORDER NOW Drug Eluting Stents Handbook edited by Patrick W. Serruys and Anthony H. Gershlick 2005 • 336 pages • $328.95 + shipping Texas residents please add 6.75 % sales tax